Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better I...
October 05 2015 - 8:00AM
Business Wire
– Initial Findings from Global Survey of
People Living with Relapsing Multiple Sclerosis (RMS) and Care
Partners to be Shared at ECTRIMS –
Genzyme, a Sanofi company, today announced a new global
initiative, vs.MS, that is designed to raise awareness of the often
unspoken emotional and physical burden of relapsing multiple
sclerosis (RMS) on people living with the disease and their care
partners. To better understand the full burden associated with RMS,
Genzyme fielded a global survey among more than 1,500 people living
with RMS and their care partners across seven countries. An initial
set of data from the vs.MS global survey will be shared for the
first time at the 31st Congress of the European Committee on the
Treatment and Research in Multiple Sclerosis (ECTRIMS) in
Barcelona, Spain, October 7-10.
“As part of our ongoing commitment to help improve the lives of
people living with MS, we are proud to introduce this new global
initiative in collaboration with patients and caregivers,” said
Darlene Jody, Head of MS Medical Affairs at Genzyme. “At Genzyme,
we believe that when we know more, we can do more. The experiences
uncovered through the vs.MS survey will help shed light on the
physical and emotional toll RMS can have, and we look forward to
developing a program that may help drive a more open exchange for
better informed care.”
While at ECTRIMS, Genzyme is bringing together thought leaders
from across the MS Community representing people living with MS,
healthcare providers specializing in the disease, and advocacy
groups to review the full vs.MS survey findings and begin
developing a program that will be rolled out to the community.
To unveil the initial vs.MS survey results at ECTRIMS, Genzyme
is hosting an interactive digital experience at their booth, as
well as sharing the findings via the @GenzymeCorp Twitter handle.
For each individual who participates in the interactive digital
experience and for every retweet that includes the campaign hashtag
#vsMS, Genzyme will donate 5 Euros to the Multiple Sclerosis
International Federation (MSIF) in support of the organization’s
research efforts.
Data from the vs.MS global survey will provide a glimpse into
the impact the disease may have on various aspects of day-to-day
life for people living with RMS. For example, half of respondents
feel their ability to progress in their career has changed for the
worse since they were diagnosed with RMS, and 40 percent are
concerned about being able to keep their job.
The vs.MS survey also reveals the effect of RMS on the emotional
well-being of those living with the disease and their care
partners. For example, more than half of respondents living with
RMS feel lonely or isolated because of their MS, while more than
half of care partners do not discuss their fear of MS progressing
to avoid upsetting the person they care for.
“The results of this global survey offer a unique look into the
realities of relapsing MS, including the challenges that people
living with MS and their care partners deal with on a daily basis,”
said Dr. Barry Singer, MD, Director of The MS Center for
Innovations in Care at Missouri Baptist Medical Center in St.
Louis, MO, and a vs.MS steering committee member. “We are hopeful
that insight into the daily struggles of those living with MS will
result in better disease management.”
The vs.MS survey was fielded among more than 1,500 people across
seven countries, including people living with RMS and RMS care
partners. Developed with input and guidance from a steering
committee of leading global neurologists specializing in MS, the
online survey addressed topics such as progression and disability;
cognitive challenges; relationship and intimacy issues; emotional
burden; fatigue and sensitivity; bladder and bowel challenges; and
impact of MS on careers.
In the coming months, Genzyme will reveal the full vs.MS data
set and partner with the MS Community to encourage behavior and
attitude shifts in an effort to drive better outcomes for those
affected by the disease.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of
transformative therapies for patients affected by rare and
debilitating diseases for over 30 years. We accomplish our goals
through world-class research and with the compassion and commitment
of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the
lives of the patients and families we serve. That goal guides and
inspires us every day. Genzyme’s portfolio of transformative
therapies, which are marketed in countries around the world,
represents groundbreaking and life-saving advances in medicine. As
a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at
www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All
rights reserved.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs.
Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative
drugs, consumer healthcare, emerging markets, animal health and the
new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New
York (NYSE: SNY).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151005005548/en/
Genzyme Media RelationsErin Walsh, +1 (617)
768-6881Erin.Walsh@genzyme.com
Banco Santander (NYSE:SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Banco Santander (NYSE:SAN)
Historical Stock Chart
From May 2023 to May 2024